HealthCap — Full Portfolio

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).

BiotechHealthtechSouth San Francisco, US

SGSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJSJavier Szwarcberg(Chief Executive Officer)in

BoardSimpson Camilla(Director)TATiba Aynechi(Director)inBMBali Muralidhar(Director)in

Board seatJHJonas Hansson· per SEC Form D

Co-investorsAIAisling CapitalRIRiverVest Venture PartnersABAbingworthNONorwest Venture PartnersNONovo HoldingsOMOmega Funds+1 more

Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsACAccess BiotechnologyAVAvoro Capital AdvisorsNONovo HoldingsSOSofinnova PartnersRARA Capital

Doctrin provides a communication platform that helps healthcare providers digitize the patient journey, including structured medical history intake and case triage to the right clinical professional.

Digital HealthEnterprise SoftwareHealthtechSaaSStockholm, SE

Co-investorsNONorrsken VCNONorrsken Accelerator

Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis.

BiotechDigital HealthFemTechMedical DevicesStockholm, SE

PSPatric Stenberg(Founder)GEGunilla Ekström(Founder)in

Co-investorsAMAmboy Street VenturesFOForeground CapitalHAHadean VenturesINIndustrifondenXGXGEN VentureCACatalyze Capital

Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine).

BiotechHealthtechMedical DevicesStockholm, SE

BHBörje Haraldsson(Research lead)inJNJenny NyströminUlf NilssonLisa BuvallinPFPål FalckinSDSusanna Dahlgren(Chief Operating Officer)in

Co-investorsFSFSGGUGU Ventures AB

Priothera is a clinical-stage biotech developing mocravimod (an S1P receptor modulator) for hematologic malignancies such as acute myeloid leukemia.

BiotechHealthtech

FGFlorent Gros(Chief Executive Officer and Founder)SOStephan Oehen(Chief Operating Officer and Founder)inBrice Suire(Chief Financial Officer and Founder)NCNigel Clark(Chief Business Officer)JHJens Hasskarl(Chief Medical Officer)

Co-investorsFOFountain Healthcare Partners4S4see Ventures

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

RBRay Barlow(Chief Executive Officer)in

Co-investorsBIBioqube VenturesFOForbionGIGimvMEMedicxiRERed Tree Venture

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.

BiotechHealthtech

OKOle Kaasbøll(Co-founder)

Co-investorsINIndustrifondenINInnovestor VenturesLILifeArc VenturesINInvestinorNONovo Holdings

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsKUKurma PartnersNONovartis Venture FundRORoche Venture FundYSYsios CapitalCOColumbus Venture PartnersEUEurazeo+1 more

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.

BiotechDigital HealthMedical DevicesBrisbane, US

CACarlos A. Schuler(Executive Officer, Director)inJSJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)GCGrace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)

BoardMcCarthy Reenie(Director)

Board seatJCJohan Christenson· per SEC Form D

Co-investorsASAsset Management CompanySOSofinnova VenturesDEDeerfield Management Company

BiotechRaleigh, US

Jaikrishna Patel(Executive Officer)Pierre Legault(Executive Officer, Director)inJames Mitchum(Director)JHJohn Hamill(Executive Officer)in

BoardRobert Seltzer(Director)

Board seatESEugen Steiner· per SEC Form D · $28.5M raise · filed Nov 2015

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.

BiotechDigital HealthMedical Devices

Co-investorsVIVida VenturesYSYsios CapitalJEJeito Capital

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVIVida VenturesJEJeito CapitalNONovo HoldingsOROrbiMedPOPontifax Venture CapitalRARA Capital+3 more

Aerogen develops aerosol drug delivery systems for hospital and ICU use, enabling targeted delivery of proteins, peptides, and solutions to the lungs.

Deep TechHardwareHealthtechMedical DevicesGalway, IE

JPJohn Power(Founder & CEO)in

Co-investorsTETemasekWEWestern Technology Investment

Affibody is a biotechnology company developing radiopharmaceuticals and radioligand therapeutics based on its proprietary Affibody platform, aimed at treating cancer patients.

BiotechHealthtech

Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.

Co-investorsADAdvent Life SciencesBIBirk VentureABAbingworth

AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinköping, SE

Magnus Borga(Co-Founder)inODOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in

Co-investorsINIndustrifondenPFPfizer Venture Investments

RxList is an online medical resource providing detailed pharmaceutical information on brand and generic drugs, written and reviewed by pharmacists and physicians.

Digital HealthHealthtechMedia & EntertainmentSan Clemente, US

Co-investorsACACVC PartnersALAlleyCorpANAnzu PartnersCOConstellation Technology VenturesINIn-Q-TelMAMaverick Silicon+4 more

Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.

BiotechDigital HealthMedical DevicesDoylestown, US

JPJohn P. Hamill(Executive Officer)inOGOren Gilad(Chief Executive Officer, President)in

BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)

Co-investors5A5AM VenturesRORobin Hood VenturesRORosetta Capital Ltd.VEVersant VenturesSOSoleus Capital

Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.

BiotechHealthtechPhiladelphia, US

KOKaryn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)

BoardElizabeth Anderson(Director)BPBruce Peacock(Director)

Co-investorsAVAvego BioScience CapitalAGAgent CapitalBIBiotechnology Value FundCOCowen Healthcare InvestmentsJOJohnson & Johnson Innovation – JJDCNONorthpond Ventures

BiotechSan Leandro, US

SASteve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inSWStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKSKenneth Schwartz(Executive Officer)inEYEric Yuen(Executive Officer)inMSMarten Steen(Director)in

Co-investorsEQEQT Life SciencesINInkefSESectoral Asset ManagementSOSofinnova VenturesYSYsios Capital

BoneSupport develops synthetic bone graft substitutes that remodel to match patient bone and elute antibiotics to prevent infection during healing.

BiotechHealthtechMedical Devices

Co-investorsINIndustrifonden

CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).

BiotechPhiladelphia, US

SKSteven Kelly(Executive Officer, Director)in

BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)RHRegina Hodits(Director)in

Co-investorsAGAgent CapitalAJAju IB InvestmentANAnzu PartnersGRGrazia Equity GmbHMRMRL Ventures FundSOSolasta Ventures+3 more

Carmeda develops the CARMEDA BioActive Surface, a heparin-based coating technology that it licenses to medical device manufacturers worldwide for use on their approved products.

BiotechMedical DevicesNew Materials

BiotechRadnor, US

Ruth Thieroff-Ekerdt(Executive Officer)Robert Lutz(Executive Officer)Alexander Lindstrom(Executive Officer)Matthew Pauls(Executive Officer)

BoardEigil Stray Spetalen(Director)Espen Tidemann Jorgensen(Director)

Co-investorsBIBirk Venture

CurifyLabs develops an automated compounding system for pharmacies that uses robotics, GMP-manufactured excipient bases, and integrated quality control software to enable faster, safer preparation of customized medications.

Digital HealthHealthtechMedical DevicesHelsinki, FI

CTCharlotta Topelius(CEO & Founder)inNSNiklas Sandler TopeliusNSNiklas Sandler(CTO & Founder)in

Co-investorsLILifeline VenturesSASandwaterTETesi (Finnish Industry Investment Ltd)

Cytos is an orthobiologics company that develops biologic treatments for orthopedic conditions.

BiotechHealthtechMedical Devices

Co-investorsAIAisling Capital

Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology.

BiotechHealthtechDüsseldorf, DE

RSRyan Spencer(Chief Executive Officer)inDNDavid Novack(President and Chief Operating Officer)inRJRobert Janssen(Chief Medical Officer and Senior Vice President, Clinical Development)inKMKelly MacDonald(Chief Financial Officer)inJCJeff Coon(Chief Human Resources Officer)DCDonn Casale(Chief Commercial Officer)in

Co-investorsBABain Capital Life SciencesSASanderling Ventures

Biopharma developing HDL-C regulating therapies; listed 2000.

BiotechAnn Arbor, US

Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)

BoardDaniel Janney(Director)Dov A. Goldstein(Director)NVNicole Vitullo(Director)inPEPatrick Enright(Director)in

Co-investorsAIAisling CapitalALAlta PartnersARArboretum VenturesARARCHIMED JapanASAsset Management CompanyCACanaan Partners+3 more

Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.

BiotechSan Carlos, US

HYHugh Y. Rienhoff, Jr., M.D.(Executive Officer, Director)in

BoardMSMarten Steen(Director)inDennis Henner, Ph.D.(Director)Bryant E. Fong(Director)

Co-investorsMCMC Healthcare VenturesCLClarus Ventures

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

JVJohn Valliant(Founder)in

Co-investorsFAFACIT (Fight Against Cancer Innovation Trust)LULumira VenturesPIPivotal Life SciencesSESeroba Life SciencesVEVenture OntarioYSYsios Capital+6 more

Hannes Klöpper(Founder)inAmit Gupta(Founder)in

Co-investorsCRCrane Venture PartnersKIKickstart InnovationXAXAnge

Intervacc develops veterinary vaccines based on recombinant protein fusions.

AgTechBiotechHealthtechMedical DevicesStockholm, SE

JSJonas Sohlmanin

Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.

BiotechDeep TechHealthtechMedical Devices

MTMohit Trikha(CEO)inSRSophia Randolph(Chief Medical Officer)in

Co-investorsBIBioGeneration VenturesBOBOMGIGimvM M VenturesRERed Tree VentureNONovo Holdings

Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.

BiotechHealthtechSouth San Francisco, US

YWYael Weiss(Founder)in

BoardCSCamille Samuels(Director)inMSMarten Steen(Director)inSSShalini Sharp(Director)inStephen Farr(Director)

Co-investorsDRDroia VenturesHBHBM Healthcare InvestmentsHBHBM PartnersMIMitsui Global InvestmentVEVenrock

Modus is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide, as a treatment for conditions with high unmet medical need including sepsis and septic shock, severe systemic inflammation such as severe malaria, and anemia related to chronic inflammation like kidney disease.

Biotech

Neobiomics develops multi-strain food supplements rooted in academic research, with collaborations across Europe.

BiotechFoodTechHealthtechMedical DevicesWellness & FitnessStockholm, SE

PNPhilipp Novak(Co-founder)inSJStefan Johansson(MD PhD, CMO)in

Norwegian clinical-stage biotech developing radiopharmaceuticals for hematological cancers; listed 2015.

Co-investorsBIBirk Venture

Oncopeptides develops therapeutics for cancer treatment.

BiotechHealthtechMedical Devices

Co-investorsINIndustrifonden

OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.

HealthtechMedical DevicesBridgewater, US

Co-investorsA-A-Rod CorpCACanaan PartnersFRFrazier Life SciencesOAOak Investment PartnersDODomain Associates

OxThera develops a live biotherapeutic product based on oxalate-degrading bacteria to treat primary hyperoxaluria and other rare kidney diseases.

BiotechHealthtechMedical DevicesStockholm, SE

Elisabeth Lindner(Chief Operating Officer)Mats-Olof Wallin(Chief Financial Officer)Milt Allison

Co-investorsSUSunstone CapitalYSYsios Capital

Positrigo develops functional imaging technology to make diagnostic and clinical imaging scalable and accessible globally.

Deep TechHardwareHealthtechMedical Devices

JFJannis Fischer(Founder)in

Co-investorsKIkineo finance

Co-investorsBIBioMedPartnersINInkefPOPontifax Venture CapitalV-V-Bio VenturesFOForbion

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.

BiotechDeep TechHealthtechMedical Devices

MMMichal Minczuk(Co-Founder)inGMGabriel Martinez(Chief Scientific Officer & Co-Founder)CGClaes Gustafsson(Co-Founder)MFMaria Falkenberg(Co-Founder)NLNils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)

Co-investorsARARCH Venture PartnersCACambridge Innovation CapitalEIEIR VenturesANAngelini VenturesGVGV (Google Ventures)INInvus+2 more

Developing safe, long-lasting gene therapy treatments in a redosable, non-viral format.

Louis Breton(Founder)in

Co-investorsOROrbiMedFOForbion

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.

Biotech

Co-investorsCDCDP Venture CapitalIRIreland Strategic Investment FundADAdams Street PartnersGEGenesys CapitalOROrbiMedPIPivotal Life Sciences+1 more

Circio is a biotech company developing circular RNA technology (circVec) to improve AAV gene therapy expression for the treatment of genetic diseases.

BiotechDeep TechHealthtech

Co-investorsBIBirk Venture

Vicore Pharma is a clinical-stage biopharmaceutical company developing disease-modifying treatments for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis.

BiotechHealthtechMedical Devices